Compare Organon & Co. Common Stock (OGN) vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. (ZTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. trades at $19.97 (market cap $15.45B). The key difference: ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. is far larger — about 4.3× Organon & Co. Common Stock's market cap, and ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. pays the higher dividend (3.34%). Which is the better fit depends on your goals.
| OGN | ZTO | |
|---|---|---|
Market Cap | $3.62B | $15.45B |
Volume | 2,892,999 | 1,928,522 |
Sector | Health | Industrials |
52-Week High | $13.81 | $25.88 |
52-Week Low | $5.70 | $18.59 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $11.04B | $14.06B |
Dividend Yield | 0.58% | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
ZTO Express trades at $20.67, up 1.08% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with $49.1B revenue, 19.03% net margin, and attractive valuation at P/E of 10.79. Recent Q2 2026 earnings beat expectations with 11% EPS growth, while analyst consensus remains strongly positive with 70% buy ratings.
ZTO presents compelling value with 50% upside to consensus target of $30.85, supported by pricing power and cost efficiencies. Risks include competitive pressures in China's delivery market and negative cash flow trends. The stock offers growth potential through market share gains and improved pricing environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.
ZTO Express provides domestic and international express delivery services in China. Its network-partner model combines ZTO's sorting and trunk transportation with partners' pickup and last-mile delivery.
Read more on ZTO →
